mTOR Inhibitors: the Lesions Induced by Papillomavirus for Transplant Patients.

Study MOTIF : mTOR Inhibitors: the Lesions Induced by Papillomavirus for Transplant Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05198427

Acronym

MOTIF

Enrollment

Registered

2022-01-20

Start date

2022-02-14

Completion date

2022-03-31

Last updated

2022-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transplantation Organ

Brief summary

The injuries induced by Human Papillomavirus (HPV) (anogenital condyloma mainly) are more frequent among transplanted patients due to their immunosuppression. These injuries are benign but they have a negative impact on the patients' quality of life. The initial treatment is topical and then surgical. The injuries can relapse, especially among transplanted patients. The modification of the immunosuppressant treatment with a switch to mTOR inhibitors (mammalian Target Of Rapamycin) has shown its efficacy in preventing the recurrence of squamous cell carcinomas or treating Kaposi's disease. By analogy, this therapeutic strategy can be sometimes put forward to transplanted patients with HPV-induced injuries. The principal objective of this study is to describe the evolution of HPV-induced lesions in solid organ transplant patients.

Interventions

OTHERreview of medical patient file

The outcome measure is the evolution of HPV related lesions between : * favourable evolution including partial or total regression * unfavourable evolution including non-evolution or aggravation or recurrence.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patient (Age ≥ 18 years) * Transplanted patient (any organ), having developed HPV-induced lesions after transplantation * Patient followed or having been followed at Edouard Herriot Hospital (HEH) * Patient having been informed and not having objected to participating in the study

Exclusion criteria

* Transplanted patient without HPV-induced lesions

Design outcomes

Primary

Measure	Time frame	Description
Evolution of HPV related lesions in patient with switch	at inclusion	At one year of the switch by an inhibitor of mTOR then remotely of the switch (by tacking the last medical encounter) for the patients concerned by the switch.
Evolution of HPV related lesions in patient without switch	at inclusion	At one year of the first HPV related lesions care then remotely (by tacking the last medical encounter) for the patients without the switch.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026